publication date: May. 2, 2016

Head and Neck Cancers Opdivo Extends OS in Phase III Squamous Cell Carcinoma Trial   

A phase III trial of PD-1 inhibitor Opdivo showed significant survival benefit at one year—compared to investigator’s choice of methotrexate, docetaxel or cetuximab—in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Patients treated with Opdivo (nivolumab) experienced a 30 percent reduction in the risk of death, with a median overall survival of 7.5 months (95% CI: 5.5-9.1) compared to 5.1 months (95% CI: 4.0-6.0) for investigator’s choice (HR=0.70 [97.73% CI: 0.51-0.96] p=0.0101).

The one-year survival rate for Opdivo was 36 percent compared to 16.6 percent for investigator’s choice. The safety profile of Opdivo in CheckMate-141 was consistent with prior studies, with no new safety signals identified.

Data from the study, CheckMate-141, were presented at the annual meeting of the American Association for Cancer Research by the drug’s sponsor, Bristol-Myers Squibb, during the meeting’s official press program and at the Immuno-Oncology Clinical Trials II Plenary Session.

CheckMate-141 is an open-label, randomized trial evaluating patients with recurrent or metastatic SCCHN with tumor progression within six … Continue reading CCL April – Opdivo Extends OS in Phase III Squamous Cell Carcinoma Trial

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.